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ABSTRACT Systemic lupus erythematosus (SLE) is an
autoimmune disorder characterized by production of autoan-
tibodies against intracellular antigens including DNA, ribo-
somal P, Ro (SS-A), La (SS-B), and the spliceosome. Etiology
is suspected to involve genetic and environmental factors.
Evidence of genetic involvement includes: associations with
HLA-DR3, HLA-DR2, Fc! receptors (Fc!R) IIA and IIIA, and
hereditary complement component deficiencies, as well as
familial aggregation, monozygotic twin concordance >20%, "s
> 10, purported linkage at 1q41–42, and inbred mouse strains
that consistently develop lupus. We have completed a genome
scan in 94 extended multiplex pedigrees by using model-based
linkage analysis. Potential [log10 of the odds for linkage (lod)
> 2.0] SLE loci have been identified at chromosomes 1q41,
1q23, and 11q14–23 in African-Americans; 14q11, 4p15,
11q25, 2q32, 19q13, 6q26–27, and 12p12–11 in European-
Americans; and 1q23, 13q32, 20q13, and 1q31 in all pedigrees
combined. An effect for the Fc!RIIA candidate polymor-
phism) at 1q23 (lod # 3.37 in African-Americans) is syntenic
with linkage in a murine model of lupus. Sib-pair and
multipoint nonparametric analyses also support linkage (P<
0.05) at nine loci detected by using two-point lod score analysis
(lod > 2.0). Our results are consistent with the presumed
complexity of genetic susceptibility to SLE and illustrate
racial origin is likely to inf luence the specific nature of these
genetic effects.
Systemic lupus erythematosus (SLE) is a complex autoimmune
disease with female predominance (!90%), particularly during
child-bearing years. African-Americans are three times as likely
to be affected as European-Americans. Clinical manifestations
variably include rashes, arthritis, nephritis, serositis, cerebritis,
and amelange of serological abnormalities. The hallmark feature
of SLE is the production of autoantibodies reactive with nuclear
components, perhaps initiated during apoptotic events. Deposi-
tion of autoantibodies and immune complexes contributes to
tissue injury, although the mechanisms underlying the pathogen-
esis of lupus are not fully understood.
Etiology of lupus is related to genetics and the environment,
possibly involving Epstein–Barr virus (1, 2). Evidence for the
importance of genetic components is demonstrated by familial
aggregation, where 7–12% of first- and second-degree relatives
have lupus, compared with European population prevalence of
about 1 in 2,000. Concordance among monozygotic twins is
!20%, whereas dizygotic twins and other full siblings have only
a 2–5% rate of concordance. Association studies have implicated
numerous candidate loci, such as HLA (DR3 and DR2 alleles),
Fc! receptors (Fc!R) IIA and IIIA, and hereditary complement
component deficiencies. Linkage has been reported in a collec-
tion of 52 sib-pairs for a candidate region at chromosome
1q41–42. Multiple susceptibility loci have been mapped for
inbred mouse strains that consistently develop lupus (3–13).
We have screened the human genome for linkage to SLE in
94 pedigrees containing 220 affecteds and 533 total subjects.
Genotypes were performed for 312 microsatellites from the
version 8 Weber Screening Set plus 12 additional candidate
markers on chromosome 1. The 31 African-American and 55
European-American pedigrees were analyzed separately as
well as combined into a total collection of 94 pedigrees. Six
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screening models were tested by two-point parametric log10 of
the odds for linkage (lod) score analysis using variable pen-
etrance values, including one adopted from a segregation
analysis for autoimmunity (14). Any marker that obtained a lod
score!1.5 in any of the screeningmodels was further evaluated
for linkage by maximizing penetrance values for males and
females. Other evidence for linkage then was sought at these
loci from the nonparametric analysis of GENEHUNTER-PLUS
and allele sharing among affected sib-pairs. We report evi-
dence for linkage to 16 potential SLE susceptibility loci,
including an effect for the Fc!RIIA polymorphism previously
shown to be associated with lupus nephritis in African-
Americans.
METHODS
Pedigrees. Enrollment required at least four of the 1982
American College of Rheumatology criteria for classification
of SLE (15) in two pedigree members whose relationship was
potentially informative for linkage. Diagnosis was verified for
all affected individuals through extensive medical record re-
view and patient interview. Seven reportedly affected individ-
uals were classified as unknown for the linkage analysis
because the diagnosis could not be confirmed. After informed
consent, blood samples were collected from 533 individuals in
94 SLE pedigrees. Genomic DNAwas isolated from peripheral
blood mononuclear cells, buccal cell swabs, or lymphoblastoid
cell lines by using standard methods. Thirty-five of the pedi-
grees comprise cohort A of the Lupus Multiplex Registry and
Repository (http:!!omrf.ouhsc.edu!lupus).
Genotyping. A total of 312 microsatellite markers were
typed from the version 8 Weber Screening Set. PCRs were
performed in 10-"l reaction volumes containing 17 ng of
template DNA, 0.20 "M of M13 tailed primers (Research
Genetics, Huntsville, AL), 0.05 "M of IR40-labeled M13
primer (Li-Cor, Lincoln, NE), 200 "M of each nucleotide, 10
FIG. 1. Summary of genome-wide scan. Maximum two-point lod scores #1.0 obtained by using six screening models for each marker are
indicated. Each E along the abscissa represents a genotyped marker from the version 8 Weber Screening Set. Markers from this set that have not
been evaluated are indicated (Ø). Approximate locations of centromeres are represented by ■.
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mM Tris!HCl (pH 8.3), 1.50 mMMgCl2, and 0.40 units of Taq
DNA polymerase. Twelve additional markers mapped to re-
gions at or near candidate regions were amplified by using a
similar protocol that internally labeled the products with 0.40
"M IR770-9-dATP (Boehringer Mannheim). Allele-specific
primers (Molecular Biology Resource Facility, University of
Oklahoma Health Sciences Center) were used to amplify the
Fc!RIIA polymorphism. Amplified fragments were detected
by using 6% polyacrylamide gels electrophoresed on auto-
mated Li-Cor model 4000 DNA sequencers. Gel images were
collected by using BASE IMAGIR version 2.0 software, and
alleles were determined by using the GENE IMAGIR version 2.0
program. Initial genotyping of the screening markers for 29
pedigrees was performed by the Mammalian Genotyping
Center in Marshfield, WI (http:!!www.marshmed.org!
genetics) by using a f luorescent-based detection system.
Marshfield data were reconciled and validated by repetitive
genotyping of selected samples as described above.
Linkage Analysis. The analytical approach developed for
screening the data was designed to maximally use all available
information from both extended and sib-pair pedigrees, and to
increase our capacity to detect genetic effects that may differ
by ethnic background. Three groups of pedigrees were ana-
lyzed: all pedigrees and two subsets consisting of 31 African-
American and 55 European-American pedigrees.
Parametric Analysis. Two-point lod scores were calculated
by using FASTLINK and the ANALYZE package, version 3.0
(16–18). A panel of six inheritance models were assumed for
screening analyses. Three dominant inheritance models in-
cluded penetrance values of 90% and 50%, in addition to a
mixed inheritance model with 92% for females and 49% for
males (14). Similarly, three recessive models with 100%, 50%,
and mixed penetrance values were evaluated. Frequency of the
disease allele was assumed to be 0.1000 for all models. Marker
allele frequencies were calculated from all available pedigree
data. All lod scores were calculated under heterogeneity by
using the HOMOG subroutine of the ANALYZE package. After
screening analysis, the estimates for loci with lod scores !1.5
were further maximized over the penetrance function. Affect-
eds-only analyses were performed for Fc!RIIA as described by
Terwilliger and Ott (19). Some parametric analyses also were
done by using GENEHUNTER-PLUS, version 2.0 (20, 21).
Nonparametric Analysis. Nonparametric linkage scores
were calculated for the complete marker set by using the
multipoint algorithm in GENEHUNTER-PLUS, version 2.0 on a
Sun Ultra 2 Workstation. The SIBPAIR routine of the ANALYZE
package was used for identifying excess allele sharing among
sib-pairs.
RESULTS
Genome Scan Identifies Potential SLE Susceptibility Loci.
Throughout the somatic chromosomes, 42 markers generated
screening lod scores !1 in one of the two racial groups or in
the entire pedigree collection (Fig. 1). No evidence for linkage
(lod !1) was found for any marker on chromosomes 8, 9, 10,
16, or 22. Maximized lod scores for 16 loci with a screening lod
score !1.5 reveal multiple possible genetic effects in lupus
(Table 1). Of these, markers Fc!RIIA (lod " 3.45), D13s779
(lod " 2.50), and D20s481 (lod " 2.49) had the greatest effect
in the combined collection of 94 pedigrees. Seven loci achieved
a maximum lod score above 2.0 for the European-American
pedigrees. Evidence for linkage in the African-American
pedigrees was found on chromosomes 1, 3, and 11.
Evidence for Linkage to Chromosome 1q. We considered
the Ig Fc receptor genes at chromosome 1q23 to be the best
candidates for linkage based on data in both humans and
murine lupus models (4–6, 13, 22, 23). Also, linkage at 1q41
had been reported (12). The maximum two-point lod scores
obtained by using the six screeningmodels shows amajor effect
at Fc!RIIA in the African-American pedigrees (Fig. 2a).
Indeed, all of the recessive models tested and the dominant
model with mixed penetrance (92% female and 49% male)
obtained lod !3.0. Further attempts to maximize the best
recessive screening model in the African-Americans yielded a
final lod score of 3.37 with 85% penetrance in females and 60%
penetrance in males at no recombination ($ " 0) with 100%
homogeneity (% " 1.0) (Table 1).
When the parametric algorithm from GENEHUNTER-PLUS
was applied to these data at Fc!RIIA, a maximum two-point
Table 1. Maximized parametric analysis of potential human SLE susceptibility loci
Lod ($, %)
Chromosomal
location Marker
Ped
Grp
Model
(penetrance) GH ASP
3.50 (0.15, 1.00) 1q41 D1s3462 AA D (100, 96)
3.45 (0.00, 0.55)* 1q23 Fc!RIIA All R (18, 1) X X
3.37 (0.00, 1.00)* 1q23 Fc!RIIA AA R (85, 60) X
2.50 (0.00, 0.25) 13q32 D13s779 All R (100)
2.49 (0.00, 0.23) 20q13 D20s481 All R (100) X X
2.21 (0.10, 1.00) 14q11 D14s742 EA D (81, 1)
2.18 (0.07, 1.00) 4p15 D4s403 EA D (37) X X
2.15 (0.00, 0.25) 11q25 D11s912 EA R (100, 1) X
2.10 (0.00, 0.35) 11q14–23 D11s2002 AA D (100, 68) X
2.09 (0.00, 1.00) 2q32 D2s1391 EA D (21) X X
2.05 (0.00, 0.19) 19q13 D19s246 EA R (100)
2.04 (0.00, 0.30) 6q26–27 D6s1027 EA D (98)
2.04 (0.25, 1.00) 1q31 lamc1 All D (95, 75) X
2.01 (0.00, 0.30) 12p12–11 D12s1042 EA R (65) X X
1.88 (0.00, 0.62) 21q21 D21s1437 EA D (61) X
1.87 (0.20, 1.00) 11p13 D11s1392 AA D (98, 68)
1.68 (0.10, 0.59) 3p21 D3s1766 AA R (100)
Penetrances of the dominant (D) or recessive (R) screening models were maximized for loci with lod!
1.5 and are given in parentheses as one value for both females and males or two values (female, male
penetrance). The pedigree group (Ped Grp) is listed for African-American (AA), European-American
(EA), or the entire pedigree collection (All). The maximum lod score is followed by $, the recombination
fraction and %, the proportion of linked pedigrees.Markers where nonparametric multipoint linkage (NPL
statistic) from GENEHUNTER-PLUS (GH) or where affected sib-pair (ASP) analysis supported linkage at P#
0.05 are indicated (X).
*Maximized models for both All and AA are presented for Fc!RIIA.
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lod score of 3.93 was obtained in the African-American
pedigrees for a dominant model with 99% female and 11%
male penetrance. The difference in the maximum lod scores
obtained in the African-American pedigrees by the different
analytic methods is explained by the elimination of certain
unaffected family members of a single large pedigree because
of processing limitations of GENEHUNTER-PLUS. An affecteds-
only analysis of the African-American pedigrees in LINKAGE
produced a lod score of 3.22 under the recessive model,
suggesting that the effect observed at Fc!RIIA for this mode
of inheritance is largely from the African-American SLE
affecteds.
Affected sib-pair analyses also support linkage at 1q23
(Table 2). Support for a genetic effect in this region covers
nearly 40 cM with the most significant sharing at Fc!RIIA
(P " 0.0003 for all 78 sib-pairs) where the African-American
sib-pairs make the major contribution. These results are also
consistent with the possibility that multiple loci are linked with
lupus between 1q21 and 1q31 (Fig. 2, Tables 1 and 2).
Evidence for linkage at the Fc!RIIA locus in the European-
American pedigrees was more modest, with a maximum
two-point lod score of 1.52 by using a recessive model with 50%
penetrance ($ " 0 and % " 0.44). All pedigrees combined
yielded a screening lod score of 3.26 under the recessive model
FIG. 2. Screening lod scores for chromosome 1. Six inheritance models were evaluated for linkage at 39 loci from chromosome 1. The maximum
lod score for each model is plotted as indicated against each marker positioned according to genetic map distances in cM (total of 291 cM).
Additional genotyped markers not included in the version 8 Weber Screening Set are shown in bold. Analysis of (a) 31 African-American pedigrees
containing 72 affecteds of 166 subjects, (b) 55 European-American pedigrees containing 129 affecteds of 320 subjects, and (c) the entire collection
of 94 pedigrees containing 533 individuals, including eight pedigrees of predominantly Hispanic, Asian, Middle Eastern, or Native American origin.
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with 50% penetrance ($" 0 and %" 0.48). The maximized lod
score for all pedigrees was 3.45; however, the decreased
penetrance (18% female and 1%male) and homogeneity (%"
0.55) of this recessive model suggest the effect is mostly related
to the contribution of the African-American pedigrees.
A second chromosome 1 effect was found at D1s3462
mapped to 1q41, where the African-American pedigrees ob-
tained a screening lod of 1.95 (Fig. 2a). When maximized, this
effect arguably became the highest lod score of the entire study
at 3.50 by using a dominant model (Table 1). This marker is 16
cM telomeric to the effect previously reported for D1S229
(12), where the highest parametric screening lod score in our
study occurred in the European-Americans at 1.29 (Fig. 2b).
DISCUSSION
Results presented herein support the genetics of lupus being
complex and differing among racial groups. Of the 16 potential
SLE loci with lod! 1.5 we describe, only three result from the
combined pedigrees rather than European-American or Afri-
can-American pedigrees separately (Table 1). Indeed, the
similarities and differences between this genome scan and the
one simultaneously reported by Gaffney et al. (24) offer
important insights. Their pedigree collection is almost com-
pletely composed of European-Americans. Nevertheless, our
results are largely supported by those obtained by Gaffney et
al. (24). Of the 16 possible effects presented in Table 1, eight
have nonparametric linkage scores (Zlr) above 1.0 in one of the
nearest neighboring markers in their study, and include
D1s3462, D20s481, D14s742, D4s403, D11s2002, D2s1391,
lamc1, and D3s1766.
Identification of potential SLE susceptibility loci in humans
offers the opportunity for comparison with data from murine
models of SLE. The majority of murine SLE susceptibility loci
have beenmapped in NewZealand hybrid models, with at least
12 located outside the interval containing the murine major
histocompatibility complex, H-2. Three regions commonly
identified by linkage in the New Zealand models are mapped
to murine chromosomes 1, 4, and 7 (13, 25, 26). The murine
chromosome 1 loci, Sbw1, Sle1, and Lbw7, are of particular
interest. These loci map to a region syntenic with human
chromosome 1q23–1q31 that contains Fc!RIIA, the locus with
the most convincing effect for linkage in our data. The murine
chromosome 4 loci, Sle2, nba1, and Lbw2, map to human
syntenic regions that include chromosomes 1p32–36 and 9p21,
neither of which show evidence for linkage in our data.
Linkage of SLE-associated phenotypes tomurine chromosome
7 loci, Sle5, Sle3, and Lbw5, span a region with homology to
human chromosomes 19q13, 11p15, and 15q11 and includes
the D19s246 marker that gave a lod score of 2.05 in our data.
Genetic susceptibility to SLE in both murine models and
humans obviously is complicated, and linkage studies have yet
to identify any particular susceptibility genes for lupus in either
species. Whether or not both species share any of the same
susceptibility genes for lupus can be known only after the genes
are identified.
The linkage at Fc!RIIA has potential to be the actual
polymorphism responsible for the genetic effect. This biallelic
marker encodes for an arginine to histidine change at position
131 of the Fc!RIIA that alters receptor capacity to bind
human IgG2 and, perhaps, influences clearance of immune
complexes (4). Significant evidence for association was not
present in African-Americans when unaffected family mem-
bers or siblings were used as controls (&2 " 0.5 and 1.7,
respectively, P ! 0.05). However, this result has not been
adjusted for decreased penetrance and heterogeneity. Other
candidates nearby that have been implicated in lupus include
Fc!RIIIB, Fc!RIIIA, and the ' chain of the T cell receptor
(22, 23, 27).
In conclusion, results from this genome scan demonstrate
evidence for genetic linkage with SLE in African-Americans at
1q23 in a region syntenic to genetic effects also found in
murine models of lupus (13, 25, 26) and at 1q41. Multiple loci
throughout the genome are virtually certain to be involved in
the genetics of SLE and racial origin is likely to influence the
specific nature of these effects. Understanding the complex
genetics of lupus and, eventually, explaining the biology of
lupus undoubtedly will provide important opportunities for
improving diagnostic methods, treatment and, perhaps, even
strategies to prevent this genetically complicated autoimmune
disorder.
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